title: Biological agents for ulcerative colitis: hypes and hopes.
abstract: Ulcerative colitis (UC) is an idiopathic chronic inflammatory disease of the colonic mucosa. Over the last decade, the increasing knowledge on the pathogenic mechanisms underlying intestinal inflammation has led to the development of a number of biological agents, mainly addressed to molecules and/or pathways demonstrated to have a pathogenic role in UC. In UC, clinical course and therapeutic decisions mainly depend on disease activity and extent. While therapeutic approach to mild-to-moderate UC by using aminosalicylates and corticosteroids has been well established, treatment of severe UC is far from being satisfactory. A severe attack of UC remains a challenge to be managed jointly by gastroenterology, surgery, and intensive care units. However, the recent introduction of biological therapies has led to promising changes in the management of UC patients. Aim of this paper is to review the recent advances and future perspectives for the use of biological agents in UC.
authors.affiliation: Division of Gastroenterology, Istituto Clinico Humanitas, IRCCS in Gastroenterology, Rozzano, Milan, Italy. sdanese@hotmail.com
authors.forename: Silvio
authors.initials: S
authors.lastname: Danese
authors.forename: Erika
authors.initials: E
authors.lastname: Angelucci
authors.forename: Alberto
authors.initials: A
authors.lastname: Malesci
authors.forename: Renzo
authors.initials: R
authors.lastname: Caprilli
mesh_terms: D000208:Acute Disease; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000077552:Basiliximab; D001688:Biological Products / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003093:Colitis, Ulcerative / Q000145:classification / Q000188:drug therapy*; D000077561:Daclizumab; D004815:Epidermal Growth Factor / Q000627:therapeutic use; D051526:Fibroblast Growth Factor 10 / Q000627:therapeutic use; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D007372:Interferons / Q000627:therapeutic use; D016753:Interleukin-10 / Q000627:therapeutic use; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors; D000069442:Natalizumab; D054735:Phosphorothioate Oligonucleotides; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D013873:Thionucleotides / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; C496463:FGF10 protein, human; D051526:Fibroblast Growth Factor 10; D007074:Immunoglobulin G; C501380:MLN02 antibody, human; D000069442:Natalizumab; D054735:Phosphorothioate Oligonucleotides; D011993:Recombinant Fusion Proteins; D013873:Thionucleotides; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D004815:Epidermal Growth Factor; D007372:Interferons; D000077552:Basiliximab; D000069285:Infliximab; D000077561:Daclizumab; D020928:Mitogen-Activated Protein Kinases; C456519:visilizumab; C089753:alicaforsen